載入...
Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
Diabetes Mellitus continues to be a major non- communicable disease with global burden of 366 million at present and projected to increase to 439 to 552 million by 2030, India being the hub of diabetes. Sodium glucose transporter 2 (SGLT2) inhibitors presents a new class of anti-diabetic drugs havin...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Medknow Publications & Media Pvt Ltd
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3978932/ https://ncbi.nlm.nih.gov/pubmed/24741548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1947-2714.128471 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|